APA (7th ed.) Citation

Jaramillo, S., Le Cornet, L., Kratzmann, M., Krisam, J., Görner, M., Hänel, M., . . . Sauer, T. (2023). Q-HAM: A multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. Trials, 24(1), 1. https://doi.org/10.1186/s13063-023-07421-x

Chicago Style (17th ed.) Citation

Jaramillo, Sonia, et al. "Q-HAM: A Multicenter Upfront Randomized Phase II Trial of Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/refractory AML with FLT3-ITD." Trials 24, no. 1 (2023): 1. https://doi.org/10.1186/s13063-023-07421-x.

MLA (9th ed.) Citation

Jaramillo, Sonia, et al. "Q-HAM: A Multicenter Upfront Randomized Phase II Trial of Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/refractory AML with FLT3-ITD." Trials, vol. 24, no. 1, 2023, p. 1, https://doi.org/10.1186/s13063-023-07421-x.